Repatha subcutaneous injection 140mg pen, manufactured by Amgen, contains evolocumab (genetical recombination), a PCSK9 inhibitor used to lower LDL cholesterol and reduce the risk of cardiovascular events. It has YJ code 2189401G2026 and standard 140mg 1mL 1 kit.
Repatha subcutaneous injection 140mg pen
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →
